Catabolic Effects of Human PTH (1-34) on Bone: Requirement of Monocyte Chemoattractant Protein-1 in Murine Model of Hyperparathyroidism.

Siddiqui JA, Johnson J, Le Henaff C, Bitel CL, Tamasi JA, Partridge NC

Scientific reports10 Nov 2017Cited by 36 (Europe PMC)

PMID29127344PMCIDPMC5681546DOI10.1038/s41598-017-15563-7PepBankPUB-29127344

Summary

The bone catabolic actions of parathyroid hormone (PTH) are seen in patients with hyperparathyroidism, or with infusion of PTH in rodents. We have previously shown that the chemokine, monocyte chemoattractant protein-1 (MCP-1), is a mediator of PTH's anabolic effects on bone. To determine its role in PTH's catabolic effects, we continuously infused female wild-type (WT) and MCP-1^-/- mice with hPTH or vehicle. Microcomputed tomography (µCT) analysis of cortical bone showed that hPTH-infusion induced significant bone loss in WT mice. Further, μCT analysis of trabecular bone revealed that, compared with the vehicle-treated group, the PTH-treated WT mice had reduced trabecular thickness and trabecular number. Notably, MCP-1^-/- mice were protected against PTH-induced cortical and trabecular bone loss as well as from increases in serum CTX (C-terminal crosslinking telopeptide of type I collagen) and TRACP-5b (tartrate-resistant acid phosphatase 5b). In vitro, bone marrow macrophages (BMMs) from MCP-1^-/- and WT mice were cultured with M-CSF, RANKL and/or MCP-1. BMMs from MCP-1^-/- mice showed decreased multinucleated osteoclast formation compared with WT mice. Taken together, our work demonstrates that MCP-1 has a role in PTH's catabolic effects on bone including monocyte and macrophage recruitment, osteoclast formation, bone resorption, and cortical and trabecular bone loss.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In female wild-type mice, hPTH infusion induced significant cortical bone loss.
In plain wordsIn mice, hPTH infusion increased cortical bone loss.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone loss
Study
mousen: not reported in source
Female wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · continuous infusionAs given in this study (mouse).
Source sentences
Summary
Microcomputed tomography (µCT) analysis of cortical bone showed that hPTH-infusion induced significant bone loss in WT mice.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine its role in PTH's catabolic effects, we continuously infused female wild-type (WT) and MCP-1^-/- mice with hPTH or vehicle.
Show in the study text Report a problemFND-2912734401
02AnimalAnimal study (in vivo)Efficacy outcome
In wild-type mice, PTH infusion reduced trabecular thickness compared with vehicle.
In plain wordsIn mice, PTH infusion reduced trabecular thickness compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTrabecular thickness
Study
mousen: not reported in source
Female wild-type mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · continuous infusionAs given in this study (mouse).
Source sentences
Summary
Further, μCT analysis of trabecular bone revealed that, compared with the vehicle-treated group, the PTH-treated WT mice had reduced trabecular thickness and trabecular number.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine its role in PTH's catabolic effects, we continuously infused female wild-type (WT) and MCP-1^-/- mice with hPTH or vehicle.
Show in the study text Report a problemFND-2912734402
03AnimalAnimal study (in vivo)Efficacy outcome
In wild-type mice, PTH infusion reduced trabecular number compared with vehicle.
In plain wordsIn mice, PTH infusion reduced trabecular number compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTrabecular number
Study
mousen: not reported in source
Female wild-type mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · continuous infusionAs given in this study (mouse).
Source sentences
Summary
Further, μCT analysis of trabecular bone revealed that, compared with the vehicle-treated group, the PTH-treated WT mice had reduced trabecular thickness and trabecular number.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine its role in PTH's catabolic effects, we continuously infused female wild-type (WT) and MCP-1^-/- mice with hPTH or vehicle.
Show in the study text Report a problemFND-2912734403

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In mice, MCP-1 deletion protected against PTH-induced cortical bone loss.
In plain wordsIn mice, MCP-1 deletion protected against PTH-induced cortical bone loss.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCortical bone loss after MCP-1 deletion
Study
mousen: not reported in source
Female wild-type and MCP-1 knockout mice
Comparator
Wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Notably, MCP-1^-/- mice were protected against PTH-induced cortical and trabecular bone loss as well as from increases in serum CTX (C-terminal crosslinking telopeptide of type I collagen) and TRACP-5b (tartrate-resistant acid phosphatase 5b).
1 context sentence(design, population, supporting numbers)
Summary · context
To determine its role in PTH's catabolic effects, we continuously infused female wild-type (WT) and MCP-1^-/- mice with hPTH or vehicle.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-2912734404
05AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In mice, MCP-1 deletion protected against PTH-induced trabecular bone loss.
In plain wordsIn mice, MCP-1 deletion protected against PTH-induced trabecular bone loss.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTrabecular bone loss after MCP-1 deletion
Study
mousen: not reported in source
Female wild-type and MCP-1 knockout mice
Comparator
Wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Notably, MCP-1^-/- mice were protected against PTH-induced cortical and trabecular bone loss as well as from increases in serum CTX (C-terminal crosslinking telopeptide of type I collagen) and TRACP-5b (tartrate-resistant acid phosphatase 5b).
1 context sentence(design, population, supporting numbers)
Summary · context
To determine its role in PTH's catabolic effects, we continuously infused female wild-type (WT) and MCP-1^-/- mice with hPTH or vehicle.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-2912734405
06AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In mice, MCP-1 deletion protected against PTH-induced increases in serum CTX.
In plain wordsIn mice, MCP-1 deletion protected against PTH-induced increases in serum CTX.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum CTX after MCP-1 deletion
Study
mousen: not reported in source
Female wild-type and MCP-1 knockout mice
Comparator
Wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Notably, MCP-1^-/- mice were protected against PTH-induced cortical and trabecular bone loss as well as from increases in serum CTX (C-terminal crosslinking telopeptide of type I collagen) and TRACP-5b (tartrate-resistant acid phosphatase 5b).
1 context sentence(design, population, supporting numbers)
Summary · context
To determine its role in PTH's catabolic effects, we continuously infused female wild-type (WT) and MCP-1^-/- mice with hPTH or vehicle.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-2912734406
07AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In mice, MCP-1 deletion protected against PTH-induced increases in serum TRACP-5b.
In plain wordsIn mice, MCP-1 deletion protected against PTH-induced increases in serum TRACP-5b.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum TRACP-5b after MCP-1 deletion
Study
mousen: not reported in source
Female wild-type and MCP-1 knockout mice
Comparator
Wild-type mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Notably, MCP-1^-/- mice were protected against PTH-induced cortical and trabecular bone loss as well as from increases in serum CTX (C-terminal crosslinking telopeptide of type I collagen) and TRACP-5b (tartrate-resistant acid phosphatase 5b).
1 context sentence(design, population, supporting numbers)
Summary · context
To determine its role in PTH's catabolic effects, we continuously infused female wild-type (WT) and MCP-1^-/- mice with hPTH or vehicle.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-2912734407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.